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Background: As therapy for non–small-cell lung cancer (NSCLC) 
patients becomes more personalized, additional tissue in the form 
of core-needle biopsies (CNBs) for biomarker analysis is increas-
ingly required for determining appropriate treatment and for enroll-
ment into clinical trials. We report our experience with small-caliber 
percutaneous transthoracic (PT) CNBs for the evaluation of multiple 
molecular biomarkers in BATTLE (biomarker-integrated approaches 
of targeted therapy for lung cancer elimination), a personalized, tar-
geted therapy NSCLC clinical trial.
Methods: The medical records of patients who underwent PTCNB 
for consideration of enrollment in BATTLE were reviewed for diag-
nostic yield of 11 predetermined molecular markers and procedural 
complications. Univariate and multivariate analyses of factors related 
to patient and lesion characteristics were performed to determine 
possible influences on diagnostic yield.
Results: One hundred and seventy PTCNBs were performed using 
20-gauge biopsy needles in 151 NSCLC patients screened for the 
trial. The biopsy specimens of 82.9% of the patients were found to 
have adequate tumor tissue for analysis of the required biomarkers. 
On multivariate analysis, metastatic lesions were 5.4 times more 
likely to yield diagnostic tissue as compared with primary tumors 
(p = 0.0079). Pneumothorax and chest tube insertion rates were 
15.3% and 9.4%, respectively.
Conclusions: Image-guided 20-gauge PTCNB is safe and provides 
adequate tissue for analysis of multiple biomarkers in the majority of 
patients being considered for enrollment into a personalized, targeted 
therapy NSCLC clinical trial. Metastatic lesions are more likely to 
yield diagnostic tissue as compared with primary tumors.
Key Words: Research biopsy, Biomarker analysis, Percutaneous 
transthoracic biopsy.
(J Thorac Oncol. 2013;8: 436-442)
Lung cancer is the most common cause of cancer-related death for men and women and represents approximately 
28% of all cancer deaths.1,2 Despite advances in cancer ther-
apy, the overall 5-year survival rate remains poor, with less 
than 30% of patients being eligible for curative resection at 
the time of diagnosis.3–5 Treatment advances for cancer ther-
apy are now predicated on an understanding of the molecular 
basis of cancer, which may provide the opportunity to develop 
novel treatment strategies. Because targeted agents are known 
to be effective against specific mutations, molecular charac-
terization of the tumor and the development of prognostic and 
predictive biomarkers are critical to guiding clinical decision-
making in the pursuit of personalized cancer therapy. As a 
result, tissue, sufficient not only for tumor classification by 
cytology and histology, but also for molecular characteristics 
(e.g., epidermal growth factor receptor [EGFR] mutation, 
anaplastic lymphoma kinase [ALK] translocation), is impor-
tant to determine whether standard chemotherapy versus tar-
geted therapy would be the most appropriate treatment for the 
patients.6
Image-guided percutaneous transthoracic core-needle 
biopsy (PTCNB) is a standard diagnostic procedure, which 
is now being used to obtain tissue for research protocols in 
which molecular biomarker analysis rather than histology is 
the ultimate goal.7–10 However, little has been written about 
the safety and adequacy of the techniques used for tissue 
acquisition in research biopsies.11–13 In addition, factors such as 
tumor histology and previous anticancer treatments that could 
potentially influence the diagnostic yield in a research setting 
have not been studied. The Biomarker-integrated Approaches 
of Targeted Therapy for Lung Cancer Elimination (BATTLE) 
trial was the first completed prospective, biopsy-mandated, 
biomarker-based, adaptively randomized phase II clinical trial 
in patients with pretreated, advanced lung cancer.14 This study 
demonstrated for the first time that PTCNBs of non–small-cell 
lung cancers (NSCLCs) could provide biomarker information 
that may be used to predict response to a particular targeted 
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therapy. The purpose of this article is to report on the safety and 
reliability of using image-guided small-caliber PTCNBs for 
multiple molecular marker analysis in patients with NSCLC 
being considered for enrollment in the BATTLE trial. We also 
analyzed the patient and biopsy-related factors to determine 
possible influences on diagnostic yield.
MATERIALS AND METHODS
This was a Health Insurance Portability and Accountability 
Act (HIPAA)-compliant subset analysis of patients who under-
went PTCNB for consideration of enrollment in the BATTLE 
trial; the study was approved by the Institutional Review Board, 
and we followed the recommendations of the Declaration of 
Helsinki for biomedical research. Of the 324 patients who 
were biopsied in the BATTLE trial, 151 patients (not all of 
whom were randomized to treatment) underwent 170 PTCNBs 
and represent the subset of BATTLE patients analyzed in 
this study.14 Nineteen patients underwent a repeat biopsy: 18 
patients, who were assigned to a treatment arm and progressed 
while on protocol, underwent repeat biopsy for consideration of 
re-enrollment into the trial. The last patient underwent a second 
optional biopsy for investigational purposes of the protocol.
The medical records of these patients were reviewed for 
the following parameters: biopsy site, imaging findings, needle 
size, image-guidance, diagnostic yield, previous treatments, 
and procedural complications. Univariate and multivariate 
analyses of the following factors were performed to determine 
possible influences on diagnostic yield: age, sex, tumor histol-
ogy, history of previous radiation treatment to biopsied lesion, 
primary versus metastatic nature of the biopsied lesion, lesion 
depth from the pleura, lesion size (maximum diameter on 
computed tomography [CT] images with standard lung win-
dow settings), location and morphology, and availability of a 
fluorodeoxyglucose positron-emission tomography/computed 
tomography (FDG-PET/CT) within 6 months before biopsy. 
A biopsy, which yielded sufficient tumor tissue for evaluation 
of all 11 biomarkers required for enrollment in the protocol, 
was considered a diagnostic biopsy. Lesion morphology was 
categorized as solid mass, consolidation (areas of parenchy-
mal opacification obscuring underlying lung markings with 
or without air bronchograms), or cavitary lesion (presence of 
air-filled cavity within lung lesion). Bivariate analyses were 
conducted using Fisher’s exact tests to explore the associa-
tion of diagnostic yield with several characteristics of patients 
and lesions. A multivariate logistic regression (SAS 9.2; SAS 
Institute Inc., Cary, NC) was fitted to the data to investigate 
the presence of higher dimension associations. A p value less 
than 0.05 was considered statistically significant.
The BATTLE trial required patients to undergo a manda-
tory baseline biopsy consisting of at least two fresh PTCNBs 
before treatment randomization. The samples were assessed 
visually by the interventional radiologist (IR) performing the 
procedure, and if the initial two specimens were small or frag-
mented, additional samples were obtained if the size and location 
of the lesion permitted additional sampling in a safe manner.
The tumor tissue was immediately fixed in formalin and 
embedded in paraffin within 24 hours. A histological section 
stained with hematoxylin and eosin was used to assess the 
presence, quantity, quality, and histological type of the tumor 
tissue. Each histology section considered adequate for bio-
marker analysis had at least 200 malignant cells.14 Using at 
least 12 histology sections, the tumor tissue was tested for 11 
different biomarkers: gene mutation analysis by polymerase 
chain reaction-based sequencing for EGFR exons 18–21, 
KRAS codons 12, 13, and 61 and BRAF exons 11 and 15; two 
copy number analyses by fluorescent in situ hybridization of 
EFGR and Cyclin D1; and six protein analyses (vascular endo-
thelial growth factor [VEGF], VEGFR-2, retinoid X recep-
tors α, β, and γ, and Cyclin D1) by immunohistochemistry. 
Confirmation of the presence of adequate tumor tissue in the 
formalin-fixed and paraffin-embedded tissue specimens by 
histology examination was performed within 24 to 48 hours, 
and analysis of the 11 molecular biomarkers was performed, 
completed, and reported within 14 days. On the basis of their 
molecular characteristics, patients were assigned to one of four 
biomarker groups (EGFR, KRAS/BRAF, VEGF or retinoid X 
receptors/Cyclin D1) to receive different therapies (erlotinib, 
vandetanib, erlotinib, and bexarotene or sorafenib).14
All PTCNB procedures were performed under CT guid-
ance by a board-certified IR. Written informed consent for 
the procedure was obtained. Accepted coagulation param-
eters included platelet levels of at least 75 × 109 liter and an 
international normalized ratio less than 1.5. All biopsies were 
performed using a coaxial technique, which allowed acquisi-
tion of multiple biopsy samples using only one transgression 
through the pleura: an 18- or 19-gauge guide needle (Cook Inc.; 
Bloomington; IN) was inserted through the skin and directed 
to the periphery of the lesion; subsequently, a 20-gauge core-
biopsy needle (Quikcore; Cook Inc.) was inserted through the 
guide needle, and samples obtained after CT confirmation of 
the needle tip’s position. After the biopsy, serial inspiratory 
chest radiographs with the patient in an erect position were 
obtained over a 3-hour observation period. A chest tube with 
a Heimlich valve was inserted if the pneumothorax size was 
more than 30% of lung volume, the pneumothorax increased 
in size, or patients experienced pain, dyspnea, or a decrease 
in oxygen saturation. Patients who had chest tubes placed 
were treated as outpatients, returning the next day for chest 
tube removal.15 Patients with persistent air leaks or those with 
severe pain were admitted to the hospital for management.
RESULTS
All patients had a diagnosis of metastatic NSCLC and 
had been previously treated with chemotherapy (Table 1). 
All patients underwent PTCNB successfully, and at least 
two PTCNBs of the tumor were obtained in each patient. Of 
the biopsy samples, 82.9% (n = 141) had sufficient tissue 
for the required biomarker analysis. Univariate analyses 
showed biopsy of metastatic lesions was more likely to yield 
diagnostic tissue than biopsy of primary tumors was (Table 2) 
(94.7% versus 76.9%; p = 0.0042). Biopsy of cavitary lesions 
was less likely to yield diagnostic tissue as compared with 
biopsy of masses or consolidations (50% versus 86.7% and 
77.8%, respectively; p = 0.0315). The diagnostic yield was 
73%, 84%, and 84% for lesions less than 2 cm, 2 to 5 cm, 
and more than 5 cm in size, respectively; the differences in 
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size were not statistically significant. There was no difference 
(p = 0.54) in diagnostic yield between the cases that had an 
FDG-PET/CT within 6 months of biopsy versus those that did 
not. On multivariate logistic regression analysis, only one of 
the variables evaluated was found to be predictive; metastatic 
lesions were 5.4 times more likely to yield diagnostic tissue as 
compared with primary tumors (p = 0.0079).
Review of the imaging data in the 29 cases with nondi-
agnostic samples (Table 3) revealed that tissue yield in 23 of 
these cases potentially could have been improved. Sampling 
error was identified in nine cases in whom a different portion 
of the lesion should have been sampled (Fig. 1). Lesion selec-
tion was not optimal in 14 cases: five cases demonstrated a 
change to the morphology of the lesion after systemic or radia-
tion therapy, with three lesions becoming smaller and two 
lesions obscured by the development of adjacent consolidative 
changes or pneumonitis in the lung parenchyma. The remain-
ing nine cases had either a large lesion or multiple lesions. In 
these patients, it is possible that presence of a recent FDG-PET/
CT could have helped in selecting the best lesion (lesion with 
highest standardized uptake value in patients with multiple 
lesions) or the most viable area within a large lesion for biopsy. 
A review of the images for the last six cases with nondiagnos-
tic biopsies revealed that both lesion selection and biopsy tech-
nique were appropriate. In these patients, we believe that onsite 
cytopathologic evaluation of fine-needle aspirations or touch 
preparations of core samples has the potential to improve the 
diagnostic yield. None of the 14 cases, in which lesion selec-
tion was identified as the error category, had an FDG-PET/CT 
within 6 months of the biopsy. Similarly, four cases of sam-
pling error and three cases of unknown error had not had an 
FDG-PET/CT within 6 months of the biopsy.
The overall complication rate was 15.9% (n = 27), 
consisting of 26 cases of pneumothorax and one case of 
subcutaneous emphysema after lung biopsy. Chest tube 
placement was needed in 16 of 27 cases (59.2%; 9.4% of 
all biopsies). All, except three patients requiring chest tube 
placement, were treated as outpatients and had the chest tubes 
removed the next day, resulting in a minor (common toxicity 
criteria adverse event Gr < 2) complication rate of 14.1% (n 
= 24). The major (all common toxicity criteria adverse events 
Gr 3) complication rate was 1.8% (n = 3): Two patients who 
required prolonged chest tube drainage for treatment of pneu-
mothorax, one of whom required pleurodesis, and the other 
who required chest tube placement for subcutaneous emphy-
sema, were admitted to the hospital.
DISCUSSION
Customized therapies for patients with NSCLC can be 
designed based on the molecular marker profile. This study 
demonstrates that 20-gauge PTCNB is safe and provides 
adequate tissue for the analysis of multiple biomarkers in 
83% of patients enrolled into a personalized, targeted therapy 
NSCLC clinical trial. Although success rates and acceptable 
thresholds for diagnostic yield have been well defined in 
the setting of diagnostic biopsy, these guidelines are yet to 
be established in the research setting.16 The lower diagnostic 
yield (83%) in this research clinical trial as compared with 
average yield of approximately 93%, reported in a diagnostic 
setting, is not surprising because the purpose of the biopsy 
in a research setting is to get enough tissue sufficient not 
only for tumor classification by cytology and histology, but 
also for multiple biomarker analyses. Few studies have been 
conducted to analyze the adequacy of CNB for molecular 
profiling, and most of these studies have been limited to breast 
or liver tissue and l4-gauge needles.11,17,18 However, large-
caliber needles are generally not used for PTCNB because of 
the potential for higher risk of pneumothorax and chest tube 
insertion. Whether PTCNB, using standard 20-gauge needles, 
yields sufficient and reliable material for mutational analysis 
remains questionable.13,19
Our experience with this study demonstrates that stan-
dard biopsy tools and techniques can be applied to acquiring 
tissue for research purposes. Table 4 represents a compilation 
of more recent experiences in using small tissue samples for 
the detection of mutations in NSCLC and shows a wide varia-
tion and lack of standardization with respect to the type of 
tissue sampled, the technique by which the tissue is acquired, 
and the methodology used for mutation analysis.12,13,19–23 The 
current standard of practice for lung cancer clinical trials is to 
take samples from the original tumor for molecular analysis, 
however, this may not be an accurate representation of the cur-
rent biomarkers of the treated tumor.24–27 Furthermore, a recent 
article, reviewing tissue sampling in lung cancer, reported 
that bronchoscopic biopsy in the Marker Identification Trial 
yielded evaluable tissue for molecular profiling in only 50% 
of samples and had limited utility in other large NSCLC tri-
als (BR.21 trial, Iressa Survival Evaluation in Lung Cancer 
[ISEL], Tarceva Response in Conjunction with Paclitaxel 
abd Carboplatin [TRIBUTE], and Iressa Pan-Asia Study 
[IPASS]).7,24–27 PTCNB offers several advantages over that of 
bronchoscopic biopsy: all areas of the thorax, including the 
TABLE 1.  Patient Demographics
n (%)
Age (mean 61 yr, range 34–81 yr) <50 31 (20.5)
51–60 33 (21.9)
61–70 56 (37.1)
>70 31 (20.5)
Sex Male 86 (57.0)
Female 65 (43.0)
Ethnicity White 125 (82.8)
Hispanic 6 (4.0)
African American 9 (6.0)
Asian 11 (7.2)
Smoker Current 12 (8.0)
Former 108 (71.5)
Never 31 (20.5)
ECOG 0 27 (17.9)
1 101 (66.9)
2 23 (15.2)
Total patients 151 (100.0)
ECOG, Eastern Cooperative Oncology Group.
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mediastinum and peripheral lesions, are accessible and mul-
tiple core biopsies are possible. Three studies, only one of 
which was in the setting of a clinical trial,13 address the utility 
of PTCNB for mutation analysis in NSCLC.12,13,23 In compari-
son, our study is unique because PTCNBs of the tumor were 
acquired for the purpose of using the molecular profile to indi-
vidualize patient therapy in a clinical trial.14 The 83% diag-
nostic yield seen in the current study is lower than the 90% 
to 100% yield reported in some other studies on biopsies in a 
research setting;12,13,23 this is most likely related to the fact that 
11 different biomarkers were analyzed in our study, whereas 
the other studies reported on the adequacy of CNB for the 
analyses of one or two mutations.
This study demonstrates that the risks associated with 
transthoracic research biopsy are similar to those reported 
for transthoracic diagnostic biopsy. Pneumothorax is a com-
mon complication of transthoracic diagnostic biopsy, and 
reported rates have ranged from 0% to 61%, with most large 
series reporting pneumothorax rates in the range of 20% to 
25%, with pneumothorax aspiration or chest tube insertion 
rates ranging from 0% to 17%.28–32 Our pneumothorax rate of 
15.3% and chest tube insertion rate of 9.4%, fall within these 
accepted ranges, and demonstrates that patients who undergo 
transthoracic research biopsies are not subject to increased 
risk for complications.
Previous studies dealing with PTCNB in a diagnostic 
setting have suggested that small lesion size (< 1cm) is associ-
ated with a poor diagnostic yield.32–35 Lesion size, however, 
was not found to be a predictive factor in our study; this could 
be related to the fact that all of the lesions biopsied were larger 
than 1 cm in size. In the current study, metastatic lesions were 
more likely to yield adequate tissue for biomarker analyses 
as compared with primary tumors. In addition, presence of 
cavitation in the biopsied lesion was associated with a poor 
TABLE 2.  Univariate Analysis of Influence of Patient, Lesion, and Biopsy Variables on Likelihood of Obtaining 
Diagnostic Tissue Sufficient for Biomarker Analyses
Characteristic
No. of  
Biopsies, (n) Diagnostic n (%) Nondiagnostic n (%) p
Size, cm 0.5842
 <2 11 8 (72.7) 3 (27.3)
 2–5 135 112 (82.9) 23 (17.1)
 >5 24 21 (87.5) 3 (12.5)
Lesion biopsied 0.0042
 Primary tumor 113 87 (77.0) 26 (23.0)
 Metastatic focus 57 54 (94.7) 3 (5.3)
History of earlier radiation therapy to the 
lesion biopsied
0.5820
 Yes 28 22 (78.6) 6 (21.4)
 No 142 119 (83.8) 23 (16.2) 0.0315
Lesion morphology
 Mass/nodule 153 130 (84.9) 23 (15.1)
 Consolidation 9 7 (77.8) 2 (22.2)
 Cavitation 8 4 (50.0) 4 (50.0)
Lesion location 0.1969
 Lung 150 123 (82.0) 27 (18.0)
 Hilum/mediastinum 8 6 (75.0) 2 (25.0)
 Pleura 12 12 (100.0) 0 (0.0)
Lesion depth, cm 0.1763
 0–2 82 72 (87.8) 10 (12.2)
 2–4 66 53 (80.3) 13 (19.7)
 >4 22 16 (72.7) 6 (27.3)
Tumor histology 0.3427
 NSCLC-NOS 31 28 (90.3) 3 (9.7)
 NSCLC-SCC 26 20 (76.9) 6 (23.1)
 NSCLC-adenocarcinoma 103 86 (83.5) 17 (16.5)
 Other 10 7 (70.0) 3 (30.0)
PET-CT within 6 mo 0.5391
 Yes 76 65 (85.5) 11 (14.5)
 No 94 76 (80.8) 18 (19.2)
NSCLC, non–small-cell lung cancer; SCC, squamous cell carcinoma; NOS, not otherwise specified; PET/CT, positron-emission tomography/computed 
tomography.
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diagnostic yield; however, on multivariate analyses, this was 
not found to be predictive. The cases in the lesion selection 
problem error category represented 48% of the nondiagnostic 
biopsies. Although we did not find a difference in the diag-
nostic yield between patients with or without a recent FDG-
PET/CT, we believe that FDG-PET/CT, with its ability to 
distinguish metabolically active disease from normal tissue, 
necrosis, fibrosis, or atelectasis, may be useful for optimiz-
ing lesion selection in unclear cases, both by determining the 
best lesion for biopsy, and by defining the most viable area 
of tumor to target during biopsy. The fact that none of the 14 
cases, in which lesion selection was identified as the error 
category, had a FDG-PET/CT within 6 months of the biopsy 
indirectly supports this hypothesis. Emerging research where 
FDG-PET/CT guidance is used during biopsy to target the 
most avid regions may help to clarify this issue further.36–40 
Sampling error was the second category affecting diagnostic 
yield, and careful, preprocedural review of the diagnostic and 
functional imaging, critical to procedural planning and acquir-
ing diagnostic specimen, should be emphasized. In the six 
cases with no obvious source of error, the presence of onsite 
cytopathology assessment at the time of the biopsy procedure, 
for evaluation of either a fine-needle aspiration sample or a 
touch preparation of a CNB, may be helpful to determine tis-
sue viability and predict the adequacy of subsequent CNBs 
taken from the area.41–45 On the basis of this error analysis, 
forthcoming clinical trials (BATTLE-2 and BATTLE-FL) 
have incorporated the use of real-time cytopathology assess-
ment to determine tissue viability, and if no clear lesion can be 
selected for biopsy based on the available diagnostic imaging, 
the IR will request a FDG-PET/CT to optimize lesion selec-
tion before biopsy. It remains to be seen whether the imple-
mentation of these measures will improve diagnostic yield. In 
the future, the development of FDG-PET/CT guided biopsy 
techniques, the routine use of navigation devices, and fusion 
of diagnostic and procedural images in the interventional 
TABLE 3.  Patients with Inadequate Tissue Samples
No. of 
Patients
Descriptive Reasons for Inadequate Tissue 
Sampling Error Category Recommendations
14 Large mass without recent PET/CT (n = 4). Multiple 
lesions without recent PET/CT (n = 5). Lesion 
response to therapy (radiation or chemotherapy) 
without recent PET/CT (n = 5).
A: Lesion 
selection problem
Recent functional imaging (PET/CT) would improve lesion selection: 
determine best lesion for biopsy (highest SUV); determine most viable 
area within tumor for biopsy; distinguish between residual tumor versus 
pneumonitis or parenchymal collapse after radiation therapy.
9 Area sampled did not show FDG activity on 
prebiopsy PET/CT (n = 3).Area sampled did not 
show contrast enhancement on prebiopsy contrast- 
enhanced CT (n = 3).Needle not in lesion, edge of 
lesion biopsied (n = 3).
B: Sampling 
error
Prebiopsy review of available cross-sectional and preferably functional 
imaging (PET/CT) is essential to procedural planning. Areas suspected to 
have the most viable tumor should be targeted.
6 Needle in appropriate position within the lesion; 
reason for inadequate tissue sampling unknown  
(n = 6).
C: Unknown Onsite cytologic assessment of a fine-needle biopsy from the area may help 
to determine tissue viability and predict the adequacy of subsequent core 
biopsies taken from the area.
PET/CT, positron-emission tomography/computed tomography; SUV, standardized uptake value; FDG, fluorodeoxyglucose.
FIGURE 1. A, Case of sampling error resulting in insufficient tissue for biomarker analysis. Axial fused PET/CT image demon-
strates FDG activity (arrows) within the mediastinal nodes and the inferior, medial border of the left upper lobe lung mass. B, 
Axial CT image during lung biopsy to acquire tumor tissue for enrollment into BATTLE demonstrates a coaxial technique with 
the tip of the 19-gauge guide needle located at the periphery of the lesion (arrowhead), and the 20-gauge core-biopsy needle 
located in the lateral edge of the cavitary mass (arrow), an area, which does not correspond to the highest area of FDG uptake 
on the prebiopsy diagnostic PET/CT. PET, positron emission tomography; CT, computed tomography, FDG, fluorodeoxyglucose; 
BATTLE, Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination.
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radiology suite may also improve the likelihood of sampling 
viable tumor tissue.36–40
This study has limitations. First, despite the large number 
of biopsy cases, this study represents data from a single institu-
tion, a well-established cancer center with the requisite infra-
structure and experience capable of coordinating this endeavor. 
Second, the error categories were assigned based on a retro-
spective review of the imaging of the biopsy cases, making it 
difficult to truly establish cause and effect. In addition, our rec-
ommendations for improving the diagnostic yield in a research 
setting are not supported by numbers and statistical evidence. 
However, the purpose of analyzing the interventional radiology 
experience in the setting of this first large clinical trial using 
integral biomarker analysis from research biopsies to drive 
patient accrual and randomization is, in part, hypothesis gen-
erating, and these ideas will be evaluated in future iterations of 
the BATTLE trials. Our recommendations are based partly on 
the results of the current study and partly on applying princi-
ples, such as onsite cytopathology assessment to improve yield, 
which have been tested previously in the diagnostic setting.41–45
The era of personalized therapy for lung cancer is 
here, and although histological diagnosis remains important, 
molecular profiling, both for current treatment and most 
certainly for research, requires more robust tumor sampling. 
This study demonstrates small-caliber core-biopsy needles can 
be used to collect tissue safely and reliably during image-guided 
PTCNB for biomarker analysis in a clinical trial setting and 
validates this new paradigm for translational research in NSCLC 
patients.14 Multivariate analyses suggests that metastatic lesions 
are more likely to yield diagnostic tissue as compared with 
primary tumors. We believe that careful review of imaging data, 
especially PET-CT, if available for selecting the most appropriate 
biopsy site, and use of onsite cytopathology assessment have 
the potential of improving the diagnostic yield. However, these 
recommendations need to be validated in future studies.
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TABLE 4.  Studies Using Small Tissue Specimens for Mutation Evaluation in NSCLC
Author Yr
No. of 
Samples Sample Type
Sample  
Size
No. of 
Samples 
Acquired Mutations Evaluated Complications
Samples with 
Tissue Adequate for 
Mutation Analysis %
Shih et al. 200619 63 Formalin-fixed, 
paraffin-embedded 
needle biopsy/
aspirationa
NR NR EGFR by PCR analysis NR 100%
Otani et al. 200820 53 Wash fluid from 
PTNB
NR NR EGFR by PCR analysis NR 100%
Zudaire et al. 200821 33 Paraffin-embedded 
FNA
NR NR 5p15, EGFR, MYC, 
CEPT6, P53, Ki-
67 by FISH and 
immunocytochemistry
NR 94%
Savic et al. 2008b22 84 Cytological 
specimens
NR NR EGFR by FISH NR 95%
Chen et al. 2008c23 17 Core-needle biopsy 
(fresh frozen)
18-gauge 3 EGFR Pneumothorax 17.6%; 
Hemoptysis 11.8%; Chest 
tube insertion rate 6%
100%
Solomon et al. 
2009c13
18 Core-needle biopsy 18-gauge  
( n = 15); 
20-gauge  
(n=3)
Median =2 EGFR by direct 
sequencing or 
PCRKRAS by direct 
sequencing
Pneumothorax  
16.7%; Chest tube  
insertion rate 0%
88.9%
Cheung et al. 201012 47 Core-needle biopsy 18-gauge  
(n = 32); 
20-gauge  
(n = 15)
3 EGFR by PCR  
analysis
Pneumothorax 12.8%; 
Hemoptysis 6.4%; Chest 
tube insertion rate -5.6%
100%
Current study Tam et 
al. 2012c 
170 Core-needle biopsy 20-gauge Median =3 EGFR, KRAS, BRAF 
by PCR; EGFR and 
Cyclin D1 by FISH; and 
6 protein analyses by 
immunohistochemistry.
Pneumothorax 15.3%; 
Hemoptysis 0%; Chest  
tube insertion rate 9.4%
83%
aSamples taken from image-guided core-needle biopsies, endoscopically guided aspiration biopsies and effusion cell blocks. Tissues analyzed included lung, liver, stomach, 
subcutaneous soft-tissue metastasis and ascites.
bSamples taken from transbronchial fine-needle aspirations, bronchial washings, bronchial brushes, bronchoalevolar lavages and pleural effusions.
cIndicates prospective study.
NR, not reported; PTNB, percutaneous transthoracic needle biopsy; PCR, polymerase chain reaction; FNA, fine-needle aspiration; FISH, fluorescent in situ hybridization; EGFR, 
epidermal growth factor receptor.
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